Login to Your Account



Other News To Note


Tuesday, November 5, 2013
Anavex Life Sciences Corp., of New York, said a report has been published in Neuropsychopharmacology demonstrating that Anavex 2-73 dose-dependently blocks Tau and amyloid-beta proteins and memory deficit in a mouse model of Alzheimer’s disease (AD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription